from StocksDiva.  two major happenings set to take place on Thursday within the biotech arena: an FDA panel review of Theravance's (Nasdaq: THRX ) Vibativ for the treatment of nosocomial pneumonia, and an FDA decision on approval for Exelixis' (Nasdaq: EXEL ) experimental metastatic medullary thyroid cancer treatment, cabozantinib.

as always be very careful trading bio's